01 December 2020
Coulter Partners secures Chief Executive Officer for ObsEva
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health.
Please refer to ObsEva’s press release published on November 9th 2020: ObsEva appoints Brian O’Callaghan as CEO
Related
-
Events
US Pharma and Biotech Summit 2024 - Innovation, investment and policies for an industry in transition
16 May 2024
-
Placement News
Top global hires for large-cap, mid-cap and public companies H1-2023
13 July 2023
-
Placement News
Coulter Partners places new Chief Scientific and Chief People Officers at Totus Medicines, supporting the drug discovery company’s senior leadership expansion
21 March 2022
-
Placement News
Coulter Partners secures Chief Executive Officer for Civetta
21 September 2021